Analyst Price Target is $6.00
▲ +118.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Eliem Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 118.98% upside from the last price of $2.74.
Current Consensus is
The current consensus among 1 investment analysts is to hold stock in Eliem Therapeutics. This Hold consensus rating has held steady for over two years.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.